Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the gross margin high or low?
The gross margin of 85.91% is in line with its 5-year average of 86.46%, around the middle of its 5-year range (79.57%–90.59%).
0.39% below its 12-month average of 86.25%.
Reported quarterly gross margin; no daily interpolation. Q2 FY2026 (2026-06-30): 88.82%.
GROSS MARGIN
85.91%
GROSS MARGIN AVG TTM
86.25%
GROSS MARGIN AVG 3Y
87.91%
GROSS MARGIN AVG 5Y
86.46%
GROSS MARGIN AVG 10Y
81.34%
GROSS MARGIN AVG 15Y
78.75%
GROSS MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-0.39%
CURRENT VS 3Y AVG
-2.27%
CURRENT VS 5Y AVG
-0.64%
CURRENT VS 10Y AVG
+5.62%
CURRENT VS 15Y AVG
+9.09%
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
41.20%
median of 862 covered companies
CURRENT VS SECTOR MEDIAN
+108.49%
vs the sector median at left
Market Cap
$131.21M
Gross Margin
57.63%
TTM Avg
59.89%
3Y Avg
61.87%
5Y Avg
62.78%
Market Cap
$130.79M
Gross Margin
33.47%
TTM Avg
39.70%
3Y Avg
43.04%
5Y Avg
44.80%
Market Cap
$127.98M
Gross Margin
82.77%
TTM Avg
89.91%
3Y Avg
44.96%
5Y Avg
29.97%
Market Cap
$136.57M
Gross Margin
3.67%
TTM Avg
16.70%
3Y Avg
18.97%
5Y Avg
8.54%
Market Cap
$136.67M
Gross Margin
97.90%
TTM Avg
100.00%
3Y Avg
100.00%
5Y Avg
100.00%
Market Cap
$127.29M
Gross Margin
58.78%
TTM Avg
29.39%
3Y Avg
14.70%
5Y Avg
9.80%
Market Cap
$137.80M
Gross Margin
61.99%
TTM Avg
62.83%
3Y Avg
59.84%
5Y Avg
59.96%
| NAME | MARKET CAP | GROSS MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| LifeMD, Inc. (LFMD) | $132.03M | 85.91% | 86.25% | 87.91% | 86.46% |
| AirSculpt Technologies, Inc. (AIRS)vs › | $131.21M | 57.63% | 59.89% | 61.87% | 62.78% |
| Health Catalyst, Inc. (HCAT)vs › | $130.79M | 33.47% | 39.70% | 43.04% | 44.80% |
| Freenome, Inc. (FRNM)vs › | $133.45M | N/A | N/A | N/A | N/A |
| Pyxis Oncology, Inc. (PYXS)vs › | $127.98M | 82.77% | 89.91% | 44.96% | 29.97% |
| Organigram Global Inc. (OGI)vs › | $136.57M | 3.67% | 16.70% | 18.97% | 8.54% |
| Atrium Therapeutics, Inc. (RNA)vs › | $136.67M | 97.90% | 100.00% | 100.00% | 100.00% |
| NRx Pharmaceuticals, Inc. (NRXP)vs › | $127.29M | 58.78% | 29.39% | 14.70% | 9.80% |
| KORU Medical Systems, Inc. (KRMD)vs › | $137.80M | 61.99% | 62.83% | 59.84% | 59.96% |
| Immuneering Corporation (IMRX)vs › | $139.04M | 0.00% | 0.00% | 12.53% | 23.21% |
Gross Margin
85.9%
(Revenue - COGS) / Revenue
Gross Margin = Gross Profit / Revenue
Gross margin is the percentage of revenue remaining after the cost of goods sold, reflecting core product profitability.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | GROSS MARGIN |
|---|---|
| 2026-06-30 | 88.82% |
| 2026-03-31 | 84.85% |
| 2025-12-31 | 81.82% |
| 2025-09-30 | 87.69% |
| 2025-06-30 | 88.06% |
| 2025-03-31 | 86.84% |
| 2024-12-31 | 85.32% |
| 2024-09-30 | 90.59% |
| 2024-06-30 | 90.08% |
| 2024-03-31 | 89.58% |
| 2023-12-31 | 88.06% |
| 2023-09-30 | 87.62% |
| 2023-06-30 | 87.35% |
| 2023-03-31 | 87.28% |
| 2022-12-31 | 85.53% |
| 2022-09-30 | 84.98% |
| 2022-06-30 | 84.78% |
| 2022-03-31 | 81.93% |
| 2021-12-31 | 79.69% |
| 2021-09-30 | 79.57% |
| 2021-06-30 | 81.53% |
| 2021-03-31 | 82.07% |
| 2020-12-31 | 69.09% |
| 2020-09-30 | 84.78% |
| 2020-06-30 | 75.90% |
| 2020-03-31 | 59.12% |
| 2019-12-31 | 87.02% |
| 2019-09-30 | 78.25% |
| 2019-06-30 | 75.72% |
| 2019-03-31 | 74.88% |
| 2018-12-31 | 70.74% |
| 2018-09-30 | 82.38% |
| 2018-06-30 | 73.76% |
| 2018-03-31 | 77.87% |
| 2017-12-31 | 71.75% |
| 2017-09-30 | 73.90% |
| 2017-06-30 | 70.27% |
| 2017-03-31 | 52.09% |
| 2016-12-31 | 31.26% |
| 2016-09-30 | 31.90% |
| 2016-06-30 | 42.88% |
| 2016-03-31 | 18.47% |
| 2015-12-31 | 97.30% |
| 2015-09-30 | 73.56% |
| 2015-06-30 | 67.73% |
| 2015-03-31 | 74.26% |
| 2014-12-31 | 89.35% |
| 2014-09-30 | 56.73% |
| 2014-06-30 | 64.83% |
| 2014-03-31 | 74.49% |
| 2013-12-31 | 64.42% |
| 2013-09-30 | 81.54% |
| 2013-06-30 | 79.66% |
| 2013-03-31 | 85.96% |
| 2012-12-31 | 156.39% |
| 2012-09-30 | 64.60% |
| 2012-06-30 | 54.39% |
| 2012-03-31 | 83.44% |
